JPWO2020190990A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190990A5 JPWO2020190990A5 JP2021556462A JP2021556462A JPWO2020190990A5 JP WO2020190990 A5 JPWO2020190990 A5 JP WO2020190990A5 JP 2021556462 A JP2021556462 A JP 2021556462A JP 2021556462 A JP2021556462 A JP 2021556462A JP WO2020190990 A5 JPWO2020190990 A5 JP WO2020190990A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- cancer cells
- checkpoint inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims description 27
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 20
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims description 12
- -1 DNQ compound Chemical class 0.000 claims description 6
- 230000033590 base-excision repair Effects 0.000 claims description 6
- 230000007547 defect Effects 0.000 claims description 5
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 230000005907 cancer growth Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 101150000874 11 gene Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 101150042435 Xrcc1 gene Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819870P | 2019-03-18 | 2019-03-18 | |
| US62/819,870 | 2019-03-18 | ||
| PCT/US2020/023250 WO2020190990A1 (en) | 2019-03-18 | 2020-03-18 | Tumor-selective combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525476A JP2022525476A (ja) | 2022-05-16 |
| JPWO2020190990A5 true JPWO2020190990A5 (enExample) | 2023-03-23 |
Family
ID=72519160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556462A Pending JP2022525476A (ja) | 2019-03-18 | 2020-03-18 | 腫瘍選択的併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220160703A1 (enExample) |
| EP (1) | EP3942061A4 (enExample) |
| JP (1) | JP2022525476A (enExample) |
| KR (1) | KR20220004025A (enExample) |
| CN (1) | CN113905763A (enExample) |
| AU (1) | AU2020240035A1 (enExample) |
| BR (1) | BR112021018545A2 (enExample) |
| CA (1) | CA3130513A1 (enExample) |
| MX (1) | MX2021011301A (enExample) |
| WO (1) | WO2020190990A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128175A (ko) * | 2022-02-25 | 2023-09-04 | 주식회사 온코크로스 | 루복시스타우린을 포함하는 항암용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2619331T3 (enExample) * | 2010-09-22 | 2018-07-28 | ||
| ES2853973T3 (es) * | 2013-04-09 | 2021-09-20 | The Board Of Trustees Of The Univ Of Illionis | Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer |
| WO2017025496A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| KR20230020549A (ko) * | 2016-03-24 | 2023-02-10 | 코테라 바이오사이언스 인코포레이티드 | Tg02를 사용한 암의 치료 |
| AU2018304458B2 (en) * | 2017-07-21 | 2021-12-09 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
-
2020
- 2020-03-18 KR KR1020217033464A patent/KR20220004025A/ko not_active Ceased
- 2020-03-18 JP JP2021556462A patent/JP2022525476A/ja active Pending
- 2020-03-18 AU AU2020240035A patent/AU2020240035A1/en not_active Abandoned
- 2020-03-18 US US17/440,787 patent/US20220160703A1/en not_active Abandoned
- 2020-03-18 MX MX2021011301A patent/MX2021011301A/es unknown
- 2020-03-18 EP EP20773832.9A patent/EP3942061A4/en not_active Withdrawn
- 2020-03-18 CA CA3130513A patent/CA3130513A1/en active Pending
- 2020-03-18 WO PCT/US2020/023250 patent/WO2020190990A1/en not_active Ceased
- 2020-03-18 CN CN202080037114.7A patent/CN113905763A/zh active Pending
- 2020-03-18 BR BR112021018545A patent/BR112021018545A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway | |
| RU2480211C2 (ru) | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| US20210069147A1 (en) | Pharmaceutical combination and uses thereof | |
| JP7192011B2 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| US12109191B2 (en) | Materials and methods for inhibiting tumor growth | |
| HK1221408A1 (zh) | 用於治疗成胶质细胞瘤的组合疗法 | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP2020530467A (ja) | 癌転移を処置するためにキナーゼを標的とする方法 | |
| KR20190135028A (ko) | 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용 | |
| JP7125059B2 (ja) | ｕＰＡＲＡＰを標的にする抗体薬物複合体 | |
| WO2022201063A1 (en) | Nanoparticle composition for targeted protein degradation | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2018531273A6 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| US10457740B1 (en) | Methods and compositions for treating cancer using P2RX2 inhibitors | |
| US11583509B2 (en) | Compound for treating cancer and diabetes | |
| Ranji et al. | Nanobiotechnological approaches to overcome drug resistance in breast cancer | |
| JPWO2020190990A5 (enExample) | ||
| Arnold et al. | Innovative therapeutic strategies to overcome radioresistance in breast cancer | |
| Cao et al. | A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer | |
| KR20240012592A (ko) | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 | |
| CN119947713A (zh) | 用于精准癌症治疗的组合物及精准癌症治疗方法 | |
| US20230365673A1 (en) | Means for reducing radio- and chemotherapy resistance and adverse effects | |
| JP7541512B2 (ja) | プロドラッグおよびその医学的使用 | |
| US7977320B2 (en) | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |